Nausea, vomiting, diarrhea, and constipation are common when starting or increasing the dose of a GLP-1
Most tablet brands have been found to produce little allicin under these conditions, due mainly to low alliinase activity and prolonged disintegration times (140, 141)
Oral GLP-1 receptor agonists also present advantages: The small-molecule candidate orforglipron will complete its Phase III trial in 2025 and, if successful, may offer a lower-cost oral alternative to injectable therapies
Structured dosing also allows for better personalization based on individual response
My doctor explained that semaglutide is a GLP-1 receptor agonist that works by regulating appetite and blood sugar levels
In order to demonstrate that the 127 gene signature is related to regional emphysema severity within individuals and not to differences between donors and COPD patients or to differences in levels of emphysema between COPD patients, we repeated the same statistical analysis while only including the five COPD patients with emphysema and standardizing the Lm measurements within each patient core to a mean of zero and a standard deviation of one (Z-score)
